PROPEL Contour receives CE mark. Click here to learn more.
Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering

Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary Intersect ENT Announces Date Change for First Quarter 2021 Financial Results Announcement
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, announced that the Company has changed the date of its previously scheduled first quarter 2021 financial
View HTML
Toggle Summary EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation
Study Initiates with Registration on ClinicalTrials.gov MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 29, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it began the process of
View HTML
Toggle Summary Intersect ENT to Report First Quarter 2021 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 20, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021 .
View HTML
Toggle Summary Intersect ENT Announces Changes to its Board of Directors
- Resignation of Anthony Vernon and Appointment of Elisabeth Sandoval-Little - MENLO PARK, Calif. --(BUSINESS WIRE)--Apr. 5, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that
View HTML
Toggle Summary Dr. Neil Hattangadi Joins Intersect ENT’s Board of Directors
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 11, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced Neil Hattangadi , M.D., M.Sc . joined the Intersect ENT Board of Directors. Dr.
View HTML
Toggle Summary Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 10, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that Tom West , President & Chief Executive Officer, and Randy Meier , Executive Vice
View HTML
Toggle Summary Intersect ENT Reports Fourth Quarter and Full Year 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 9, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today reported financial results for the fourth quarter and full year ended December 31, 2020 .
View HTML
Toggle Summary CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication
Pass-Through Status Will Continue Under the New Code Through June 30, 2023 MENLO PARK, Calif. --(BUSINESS WIRE)--Mar. 8, 2021-- Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that the
View HTML
Toggle Summary Intersect ENT to Report Fourth Quarter and Full Year 2020 Financial Results
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 23, 2021-- Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced that it will release fourth quarter and full year 2020 financial results on Tuesday,
View HTML
Toggle Summary Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant
MENLO PARK, Calif. --(BUSINESS WIRE)--Feb. 11, 2021-- Intersect ENT ® , Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (“SDS”) packaged with the
View HTML